Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses some common challenges hematology oncology pharmacists face in the field during their pursuit of professional growth and development.
Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.
Karen Fancher, PharmD, BCOP, a member of the Patient Advisory Panel at the Hematology/Oncology Pharmacy Association (HOPA), explains how her experience as a patient with cancer and an oncology pharmacy specialist informs her work on HOPA’s Patient Advisory Panel.
David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.
David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses key takeaways from the HOPA 2022 annual conference.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how experience as a caregiver can help inform the work of an oncology pharmacist on the clinical care team.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists with experience as a caregiver can utilize those skills while still honoring the boundaries of both themselves and their patients.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the unique struggles that come from being an oncology pharmacist and a caregiver.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists can help their patients overcome some of the barriers patients with cancer may encounter during treatment.
Benyam Muluneh, PharmD, BCOP, CPP, assistant professor at the University of North Carolina Eshelman School of Pharmacy, discusses his presentation at the HOPA 2022 annual conference on the Oral Chemotherapy Collaborative (OCC) and how it works to optimize care for patients taking oral anti-cancer agents.
Britny Brown, PharmD, BCOP, vice chair of the Hematology/Oncology Pharmacy Association (HOPA) DEI Task Force and clinical assistant professor at the University of Rhode Island College of Pharmacy, discusses the role of the task force within HOPA and its impact on the field more broadly.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers patients with cancer may experience that oncology pharmacists can help them navigate through.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.
Session at the Hematology/Oncology Pharmacy Association Annual Conference 2022 focuses on methods to improve emotional exhaustion among pharmacists and other health care providers.
With risk stratification, up to 60% of individuals with chronic myeloid leukemia who are low-risk sustain treatment-free remission.
These include progression-free survival, time to treatment failure, and time to tumor progression, according to a presentation at the Hematology/Oncology Pharmacy Association conference.
21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.
Christy S. Harris, PharmD, BCOP, FHOPA, clinical pharmacy specialist at Dana-Farber Cancer Institute, discusses guidelines for common therapies and appropriate monitoring recommendations for selected therapies used in the treatment of adult sarcomas.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), discusses ways to address burnout in the hematology/oncology space.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.
Larry Buie, PharmD, BCOP, FASHP, outgoing president of the Hematology/Oncology Pharmacy Association (HOPA), shares some details of HOPA’s upcoming 2022 annual conference in Boston and provides an overview of his term as HOPA’s president.
Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.
Among somatic mutations, approximately 89% of patients with metastatic castration-resistant prostate cancer have a potentially actionable mutation.
Hematology/Oncology Pharmacy Association plans to develop tools and resources to support those conducting research in the oncology pharmacy field, with the goal of promoting pharmacist-led research and improving the ability to analyze difficult scientific questions.
Patient interactions became vastly different during the pandemic, with questions surrounding how to coordinate contact and how to best provide pharmacy services virtually, including counseling, fielding drug information questions, medication reconciliation, and providing home medication sheets to families
Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.
Pharmacokinetic differences in pediatric patients should be considered when administering direct oral anticoagulants, as should potential administration difficulties when pellets or oral solutions are not available.
Selection of any BTK inhibitors for mantle cell lymphoma should consider factors such as cardiovascular or bleeding risks, predisposition for gastrointestinal adverse effects, and potential medication nonadherence.
